Molecular Medicine Tri-Conference

Meet with Q2 Solutions and learn how we can help you bring drugs to patients faster by optimizing your clinical development strategies. 

San Francisco, CA | February 11, 2018 - February 16, 2018 | 08:00 - 17:00 Add to Calendar
Register to Receive Presentation Schedule a Meeting

About This Event

Q2 Solutions’ end-to-end lab services, high quality metrics-driven custom delivery strategy and global scale can help accelerate your drug and diagnostic development efforts.

With an exponential growth in the area of personalized medicine and in particular immuno-oncology, Q2 Solutions provides continuous improvement efficiency initiatives to meet customers’ individual needs. We have the deep scientific expertise to support your drug discovery, precision medicine and clinical development processes through our genomic know-how®, end-to-end biomarkers strategy and companion diagnostics services.

Make plans to attend our short course presentation, Next Generation Flow Cytometry, on Monday, February 12th at 8:00 – 11:00 am, to discover insights that can help guide your clinical project from drug discovery to development.

Schedule a meeting with our team to learn how our experienced scientists and bioinformaticians can design smarter studies to help you identify biomarkers, select the right patients and develop safer and more effective medicines faster.

We look forward to meeting you in San Francisco.

Related Services:

Register for Event


Mark Edinger
Flow Cytometry

Mark Edinger is the scientific advisor for Flow Cytometry at Q2 Solutions. As the scientific advisor, Mark is responsible for flow cytometry assay design and implementation. He works with both the Translational Biomarkers Laboratory to develop assays and the Global Cytometry Group to produce assays, and is the architect of the systems and workflows used in Q2 Solutions’ flow cytometry assay development and production laboratories.

Mark began his career at the Cleveland Clinic Foundation, a preeminent medical institution, where he pioneered flow cytometry in the late 1970s, building both clinical and research core flow cytometry laboratories. During his 21 years at the Cleveland Clinic, Mark developed many of the techniques and assays employed today for clinical practice and academic research. During this time, Mark also was a consultant for Becton Dickinson (BD) Immunocytometry Systems and participated in clinical trials of new BD products. In 1998, Mark formally joined BD where he founded the Technical Applications Group, and later the R&D Systems Validation Laboratory. While at BD, Mark, working with scientists at Amgen, developed the whole blood phosphoprotein lysing buffer that is now used daily in laboratories throughout the world. Mark joined Quintiles in 2012 and has been part of a collaboration which introduced the quantitative standardization of flow cytometers, along with other state of the art practices, making Quintiles flow laboratories the first to offer this level of instrument standardization anywhere in the world. Mark became part of the Q2 Solutions team when the company was officially launched in June 2015 as a result of a Quintiles and Quest Diagnostics joint venture.

Mark graduated from Case Western Reserve University with a Bachelor of Science degree in Biology.

Updated as of September 2018.

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options

Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Read More